As reported by Lee Hye-seon in the Korea Biomedical Review, the Korean government has approved Xofluza for a phase 3 clinical trial to evaluate the efficacy and safety of the new influenza treatment. The trail will take place at the following locations:
Catholic University of Incheon St. Mary’s Hospital, Kyungpook National University Hospital, Korea University Anam Hospital and Guro Hospital, Samsung Medical Center, Asan Medical Center, Chung-Ang University Hospital, Kangnam Sacred Heart Hospital, Wonju Severance Christian Hospital, Chungnam National University Hospital, and Bundang Seoul National University Hospital. Unlike Tamiflu which needs to be taken twice a day for five days, baloxavir marboxir (Xofluza) can be taken once daily. The most common side effects of baloxavir marboxir are diarrhea and bronchitis. The U.S. Food and Drug Administration gave the green light to baloxavir marboxir under the product labeling of Xofluza in October 2018.